ESPR — Esperion Therapeutics Share Price
Last trade - 00:00- $822.04m
- $1.21bn
- $403.14m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 25.88 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.97 | ||
| EV to EBITDA | 15.91 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 46.73% | ||
| Return on Equity | n/a | ||
| Operating Margin | 18.12% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 78.45 | 75.47 | 116.33 | 332.31 | 403.13 | 378.55 | 437.38 | 12.12% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering cardiometabolic and rare/orphan disease therapies. It markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels who are at risk of cardiovascular disease and nasal spray, loop diuretic for the treatment of edema associated with congestive heart failure, and hepatic and renal disease. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. NEXLETOL is a first-in-class ACLY inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating LDL receptors. NEXLIZET contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and cholesterol absorption in the intestine. Its Enbumyst is the FDA-approved nasal spray loop diuretic.
Directors
- Sheldon Koenig PRE (55)
- Richard Bartram CFO (39)
- Benjamin Looker GCN (39)
- JoAnne Foody OTH (56)
- Ashley Hall OTH (49)
- Nicole Vitullo LED (63)
- Jeffrey Berkowitz DRC (55)
- Seth Fischer IND (65)
- Alan Fuhrman IND (64)
- Antonio Gotto IND (85)
- Mark McGovern IND (67)
- Jay Shepard IND (63)
- Tracy Woody IND (51)
- Last Annual
- December 31st, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- January 22nd, 2008
- Public Since
- June 24th, 2013
- No. of Shareholders
- 5
- No. of Employees
- 294
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 257,693,347
- Address
- 3891 Ranchero Drive,, ANN ARBOR, 48108
- Web
- https://www.esperion.com/
- Phone
- +1 null3026587581
- Contact
- Alina Venezia
- Auditors
- Ernst & Young LLP
Latest News for ESPR
Upcoming Events for ESPR
Q2 2026 Esperion Therapeutics Inc Earnings Release
Q3 2026 Esperion Therapeutics Inc Earnings Release
Similar to ESPR
AC Immune SA
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Aurinia Pharmaceuticals
NASDAQ Global Market
FAQ
As of Today at 02:31 UTC, shares in Esperion Therapeutics are trading at $3.19. This share price information is delayed by 15 minutes.
Shares in Esperion Therapeutics last closed at $3.19 and the price had moved by +159.35% over the past 365 days. In terms of relative price strength the Esperion Therapeutics share price has outperformed the S&P500 Index by +115.92% over the past year.
The overall consensus recommendation for Esperion Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreEsperion Therapeutics does not currently pay a dividend.
Esperion Therapeutics does not currently pay a dividend.
Esperion Therapeutics does not currently pay a dividend.
To buy shares in Esperion Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.19, shares in Esperion Therapeutics had a market capitalisation of $822.04m.
Here are the trading details for Esperion Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ESPR
Based on an overall assessment of its quality, value and momentum Esperion Therapeutics is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Esperion Therapeutics is $2.91. That is 8.78% below the last closing price of $3.19.
Analysts covering Esperion Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.04 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Esperion Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -23.96%.
As of the last closing price of $3.19, shares in Esperion Therapeutics were trading +4.54% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Esperion Therapeutics PE ratio based on its reported earnings over the past 12 months is 25.88. The shares last closed at $3.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Esperion Therapeutics' management team is headed by:
- Sheldon Koenig - PRE
- Richard Bartram - CFO
- Benjamin Looker - GCN
- JoAnne Foody - OTH
- Ashley Hall - OTH
- Nicole Vitullo - LED
- Jeffrey Berkowitz - DRC
- Seth Fischer - IND
- Alan Fuhrman - IND
- Antonio Gotto - IND
- Mark McGovern - IND
- Jay Shepard - IND
- Tracy Woody - IND